Magazine article Clinical Psychiatry News

Antipsychotics Boost CVD Events in Elderly: At the Aha Scientific Sessions

Magazine article Clinical Psychiatry News

Antipsychotics Boost CVD Events in Elderly: At the Aha Scientific Sessions

Article excerpt

DALLAS - Elderly patients who started treatment with an antipsychotic drug had a substantially increased risk for a major adverse cardiovascular disease event, especially during the first month on treatment, according to Danish national records from more than 1 million people.

The risk remained elevated even when the analysis focused on elderly people who were aged 70 years or older and were without cardiovascular disease or dementia at the time of their first use of an antipsychotic medication, Dr. Charlotte Andersson and her associates reported in a poster at the American Heart Association scientific sessions.

Treatment was linked with a significantly increased rate of major adverse cardiovascular events (MACE) at some time during follow-up for all eight antipsychotic drugs studied in detail: haloperidol (Haldol). flupentixol See Antipsychotics page 3 (Fluanxol), chlorprothixene, levomepromazine (Nozinan), quetiapine (Seroquel), risperidone (Risperdal), olanzapine, and ziprasidone (Geodon), reported Dr. Andersson, a researcher at Gentofte Hospital in Copenhagen. The MACE association was relatively weak for ziprasidone, but it was robust for the other seven agents. even higher during the first 30 days of treatment for most of the eight drugs. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.